CrossRefPubMed 33. Schmitz-Drager

BJ, Schulz WA, Jurgens B, Gerharz CD, van Roeyen CR, Bultel H: c-myc in bladder cancer, clinical findings and analysis of mechanism. Urol Res 1997, 25: S45-S49.CrossRefPubMed 34. Lipponen PK: Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995, 175: 203–210.CrossRefPubMed 35. Tungekar MF, Linehan J: Patterns of expressions of transforming growth factor and epidermal growth factor receptor in squamous cell lesions C59 wnt in vivo of the urinary bladder. J Clin Pathol 1998, 51: 583–587.CrossRefPubMed 36. Masliukova EA, Pozharisskii KM, Karelin MI, Startsev V, Ten VP: [Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer]. Vopr Onkol 2006, 52: 643–648.PubMed 37. Nakopoulou L,

Vourlakou C, Zervas A: The prevalence of bcl-2, p53 and Ki-67 selleck screening library immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998, 29: 146–154.CrossRefPubMed 38. Pfister C, Moore L, Allard P, Larue H, Fradet Y: Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence. Clini Ca Res 1999, 5: 4079–4084. Competing interests The authors declare that they have no competing interests. Authors’ contributions RR and HS carried out patients sampling and interviewing in conjunction with specialist urologists. AS and F did the immunostaining procedures and examination in conjunction with specialist pathologists. AS and F carried out the paper drafting, statistical design, statistical analysis, and the proofreading of the article language and integrity. All authors read and approved the final manuscript.”
“Background Lung cancer is the leading cause of cancer death in the industrial nations [1]. Despite recent advances, therapeutic regimens support quality of life but frequently fail to increase long term survival. One of the main reasons for the failure of therapeutic regimens is the fact that cancer cells originate from Cyclooxygenase (COX) normal cells and therefore

possess Go6983 cell line similar characteristics. This means that anti-cancer therapies inevitably affect the normal cell population and these side effects often hinder more effective treatments. Thus, knowledge of the differences in the cellular physiology between malignant and non-malignant cells is crucial for the development of more successful treatments. Calcium is a ubiquitous signal molecule that is involved in almost all cellular pathways [2, 3]. Elevation of the cytoplasmic Ca2+-concentration ([Ca2+]c) can result either from Ca2+-influx from the extracellular space or from Ca2+-release from internal Ca2+-stores, primarily the ER. Proteins involved in the Ca2+-release from the ER are the inositol-1,4,5-trisphosphate receptor (IP3R) and the ryanodine receptor (RyR) (Figure 1).